Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. Schlam I, Moges R, Morganti S, Tolaney SM, Tarantino P. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. Critical reviews in oncology/hematology. 2023:104090. doi:10.1016/j.critrevonc.2023.104090 Read more